
As globalisation in the pharmaceutical industry is starting to take effect, and countries like China offer scientific work at a fraction of the Danish wage levels, Danish flagships within the area are maintaining or even increasing their staff within research and development (R&D).
That’s the conclusion of a survey of employee numbers for the last three to five years conducted by Novo Nordisk, Lundbeck and Leo Pharma on behalf of Medwatch.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app